HUMAN HEPATIC 3D SPHEROIDS AS A MODEL FOR METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE ( MASLD)

被引：0
|
作者：
Choi, Mi-Sun [1 ]
Kim, Soojin [1 ]
Jegal, Hyun [1 ]
Lee, Ga-Won [2 ]
Oh, Jungh-Hwa [1 ,2 ]
机构：
[1] Korea Inst Toxicol, Daejeon, South Korea
[2] Univ Sci & Technol, Hefei, Peoples R China
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
68
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 50 条
  • [21] ASSOCIATION BETWEEN CARDIOVASCULAR HEALTH AND METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Alebna, Pamela L.
    Yasin, Alhussain
    Harley, Kayla
    Ambrosio, Matthew
    Dixon, Dave L.
    Siddiqui, Mohammad
    Salloum, Fadi N.
    Mehta, Anurag
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2029 - 2029
  • [22] Cardioprotective Role of Beta Hydroxybutyrate in Metabolic Dysfunction -Associated Steatotic Liver Disease (MASLD)
    Badmus, Olufunto
    da Silva, Alexandre
    Taylor, Lucy
    Greer, Jennifer
    McGowan, Karis
    PHYSIOLOGY, 2024, 39
  • [23] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [24] Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine MASLD
    Stefan, Norbert
    Targher, Giovanni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 226 - 227
  • [25] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [26] INSULIN RESISTANCE IS A PREDICTOR OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND MASLD-ASSOCIATED FIBROSIS
    Kim, David S.
    Ismail, Mohamed
    Abboud, Yazan
    Khan, Wajiha
    Le, Alexander
    Pyrsopoulos, Nikolaos T.
    Kim, Hyunseok
    Hajifathalian, Kaveh
    GASTROENTEROLOGY, 2024, 166 (05) : S1657 - S1657
  • [27] 3D human liver spheroids for translational pharmacology and toxicology
    Ingelman-Sundberg, Magnus
    Lauschke, Volker M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 : 5 - 15
  • [28] Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)
    Wong, Robert J.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [29] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    LIFE-BASEL, 2024, 14 (07):
  • [30] Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
    Benede-Ubieto, Raquel
    Cubero, Francisco Javier
    Nevzorova, Yulia A.
    GUT MICROBES, 2024, 16 (01)
12345